SRPX2 promotes HUVEC angiogenesis via macrophages

doi:10.12092/j.issn.1009-2501.2018.11.005

Abstract

Abstract:

AIM: To investigate whether sushi repeat-containing protein X-linked 2 (SRPX2) can influence angiogenesis via macrophages, and its potential mechanism. METHODS: After transferring shRNA-SRPX2 and vacant shRNA vector into HCT116 cells, culture medium supernatant was extracted from three types of cells (HCT116-KD, HCT116-NC and HCT116-BC) as the conditioned medium. After culturing THP-1 induced macrophages in the conditioned medium, the macrophages were co-cultured with HUVECs for Transwell migration assay and Matrigel tube formation assay to verify the migration ability and tube formation ability of HUVECs. In addition, focal adhesion kinase (FAK) and phosphorylated FAK expression level in macrophages were measured by Western blot after activated by SRPX2 recombinant protein for 4 h. RESULTS:In migration assay, the number of HUVECs migrating to the lower chamber was significantly diminished in HCT116-KD group（P<0.01）. In tube formation assay, numbers of junctions, meshes and nodes also decreased in the HCT116-KD group（P<0.05）. As for the FAK expression, the expression of FAK as well as the phosphorylated level of FAK in macrophages elevated after interacted with SRPX2 recombination protein.CONCLUSION: SRPX2 can affect angiogenesis via macrophages, which is probably depends on FAK related signal pathways.

Key words: sushi repeat-containing protein X-linked 2 (SRPX2), macrophage, angiogenesis, focal adhesion kinase (FAK)

CLC Number:

R965.2

LI Nanshan, LIU Kuiliang, LI Qian, LAO Yueqiong, WANG Yadan, SU Hui, LIU Hong, WU Jing. SRPX2 promotes HUVEC angiogenesis via macrophages[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1228-1234.

References

［1］Carmeliet P. VEGF as a key mediator of angiogenesis in cancer［J］. Oncology, 2004, 69(Suppl.3): 4-10.
［2］Yamada T, Oshima T, Yoshihara K, et al. Impact of overexpression of Sushi repeat-containing protein X-linked 2 gene on outcomes of gastric cancer［J］. J Surg Oncol, 2014, 109(8): 836-840.
［3］Tanaka K, Arao T, Tamura D, et al. SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer［J］. Plos One, 2012, 7(1): e27922.
［4］Miljkoviclicina M,Hammel P,Garridourbani S,et al.Sushi repeat protein X-linked 2,a novel mediator of angiogenesis［J］.FASEB J,2009,23(12):4105-4116.
［5］Liu K, Fan J, Wu J. Sushi repeat-containing protein X-linked 2 promotes angiogenesis through the urokinase-type plasminogen activator receptor dependent integrin αvβ3/focal adhesion kinase pathways［J］. Drug Discov Ther, 2017, 11(4): 212-217.
［6］Bingle L, Lewis CE, Corke KP, et al. Macrophages promote angiogenesis in human breast tumour spheroids in vivo［J］. Br J Cancer, 2006, 94(1): 101-107.
［7］Lu P, Weaver VM, Werb Z. The extracellular matrix: A dynamic niche in cancer progression［J］. J Cell Biol, 2012, 196(4): 395-406.
［8］樊江浩, 刘揆亮, 周跃, 等. 细胞外基质蛋白SRPX2促进HUVECs血管生成能力［J］. 基础医学与临床, 2015, 35(10): 1336-1340.
［9］Tanaka K, Arao T, Maegawa M, et al. SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion［J］. Int J Cancer, 2009, 124(5): 1072-1080.
［10］Kurosawa H, Goi K, Inukai T, et al. Two candidate downstream target genes for E2A-HLF［J］. Blood, 1999, 93(1): 321-332.
［11］Royer B, Soares DC, Barlow PN, et al. Molecular evolution of the human SRPX2 gene that causes brain disorders of the Rolandic and Sylvian speech areas［J］. BMC Genet, 2007, 8(1): 72.
［12］Royerzemmour B,Ponsolelenfant M,Gara H,et al.Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR［J］.Hum Mol Genet,2008,17(23):3617-3630.
［13］Liu KL, Wu J, Zhou Y, et al. Increased Sushi repeat-containing protein X-linked 2 is associated with progression of colorectal cancer［J］. Med Oncol, 2015, 32(4): 99.
［14］Yamada T, Oshima T, Yoshihara K, et al. Impact of overexpression of Sushi repeat-containing protein X-linked 2 gene on outcomes of gastric cancer［J］. J Surg Oncol, 2014, 109(8): 836-840.
［15］Lin X, Chang W, Wang Y, et al. SRPX2, an independent prognostic marker, promotes cell migration and invasion in hepatocellular carcinoma［J］. Biomed Pharmacother, 2017, 93: 398-405.
［16］Gao Z, Zhang J, Bi M, et al. SRPX2 promotes cell migration and invasion via FAK dependent pathway in pancreatic cancer［J］. Int J Clin Exp Pathol, 2015, 8(5): 4791-4798.
［17］Tang H, Zhao J, Zhang L, et al. SRPX2 enhances the epithelial-mesenchymal transition and temozolomide resistance in glioblastoma cells［J］. Cell Mol Neuro biol, 2016, 36(7): 1067-1076.
［18］Birbrair A,Zhang T,Wang ZM,et al.Type-2 pericytes participate in normal and tumoral angiogenesis［J］.Am J Physiol Cell Physiol,2014,307(1):25-38.
［19］陈伟, 周赟, 龚建平. 肿瘤相关巨噬细胞在原发性肝癌发生发展中的作用［J］. 临床肝胆病杂志, 2016, 32(7): 1422-1424.
［20］Bingle L, Brown NJ, Lewis CE. The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies［J］. J Pathol, 2002, 196(3): 254-265.
［21］Wu H, Xu J, He Y, et al. Tumor‐associated macrophages promote angiogenesis and lymph angiogenesis of gastric cancer［J］. J Surg Oncol, 2012, 106(4): 462-468.
［22］李树裕,王志钢.粘附斑激酶(FAK)及其信号通路研究进展［J］.生物技术通报,2009,10(12):6-10.
［23］王丽, 张勇. SRPX2在子宫内膜癌中的表达及对HEC-1A细胞增殖凋亡的影响［J］. 实用医学杂志, 2017, 33(4): 529-532.
［24］Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications［J］. Nat Rev Cancer, 2014, 14(9): 598-610.
［25］Walsh C,Tanjoni I,Uryu S,et al.Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models［J］.Cancer Biol Ther,2010,9(10):778-790.
［26］Wendt MK, Schiemann WP. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis［J］. Breast Cancer Res: BCR, 2009, 11(5): R68.
［27］Kroon ME, Koolwijk P, Goor HV, et al. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices［J］. Am J Pathol, 1999, 154(6): 1731-1742.
［28］Simon D, Wei YL, Rao N, et al. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function［J］. J Biol Chem, 2000, 275(14): 10228-10234.

[1]	LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong. Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978.
[2]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[3]	YAO Yao, XIA Min, HOU Cong, HE Airong. Effects of ABT-737 on the growth and angiogenesis of ovarian cancer cells in the co-culture of TAMs and SKOV3 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 144-153.
[4]	ZHOU Shiqin, LUO Yali, ZHOU Wen, Qi Xiaofeng, XIAO Mengyong. Molecular mechanism and treatment of pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1133-1147.
[5]	KONG Xiang, HUA Qiang, YAO Xinming, MENG Xiangjian, ZHONG Min, GUO Liqun. Sesamol improves inflammation and insulin resistance in adipose tissue of obese mice by regulating macrophage polarization [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 728-733.
[6]	CHENG Run, DING Wenxi, YAN Shangxue, WEI Wei. Human umbilical cord-derived mesenchymal stem cells alleviate adjuvant arthritis by regulating macrophage in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1335-1340.
[7]	CAO Yingya, CHEN Qun, WANG Zhen, WU Jingyi, JIANG Xiaogan, JIN Xiaoju, LU Weihua. Role of macrophages in LPS-induced apoptosis of intestinal epithelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1142-1146.
[8]	HAN Chenyang, YANG Yi, LI Wenyang, WANG Jin, GUO Li. Inhibitory effect of MicroRNA-136 targeting CD163 on the polarization of CD68+CD163+M2 macrophages [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 1-8.
[9]	ZHAO Xiaobin, YU Chenhuan, XIA Aixiao, YU Wenying, YU Bing. Recent advances of nanocarriers targeting tumor-associated macrophages in tumor therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 830-835.
[10]	LI Jinyu, HUANG Danmei, ZHANG Yanmei, SHI Ganggang, WANG Bin. Macrophage migration inhibitory factor protects H9c2 cardiac myocytes against hypoxia/reoxygenation injury through regulation of autophagy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 531-535.
[11]	WANG Lu, LI Liping, XING Xin, XU Dengqiu, XIAO Li, JIANG Zhenzhou, ZHANG Luyong, SUN Lixin. Hepatic macrophages in liver injury and repair [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1188-1195.
[12]	ZHENG Xiao, HU Xiaosheng. Effects of rosuvastatin on hypertension with carotid atherosclerosis and its influence on peripheral macrophage polarization [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1035-1039.
[13]	CHEN Xing, WU Weiling, CHEN Shanshan, YE Liya, MEI Shuangshuang, WANG Jing, HE Yu, CHAI Zeying. Immunological pathology mechanism research of cervical cancer based on tumor related macrophage [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1394-1399.
[14]	YU Rong, JIN Hao, LIN Jinju, HUANG Xuefeng . Comparison of M-CSF and its receptor mRNA expression in luteinized granulosa cells after using recombinant human follicle stimulating hormone [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1415-1420.
[15]	CHEN Fangjun, WANG Zeng, CAI Xinjun, CAO Yingying, CHEN Pei, SHAO Yun. Anti-tumor effects of zoledronic acid-loaded stealth cationic liposome by targeting tumor angiogenesis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 33-36.